IPO registrations (S-1, F-1) · Registrants
CERENOME, INC.
- SEC CIK
- 1095981 · filings on EDGAR ↗
- Name on the registration
- PLUS THERAPEUTICS, INC.
- Former names
- PLUS THERAPEUTICS, INC. (2019–2026); CYTORI THERAPEUTICS, INC. (2005–2019); MACROPORE INC (2001–2005)
- Registration
- Form S-1, first filed 2016-04-06, last 2026-01-09; 17 initial registrations, 10 amendments
- Outcome
- Final prospectus filed 2016-05-27; declared effective 2016-05-26; withdrawal requested 2025-03-31
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus 3841
- Incorporated in
- DE
- Business address
- 6420 LEVIT GREEN BOULEVARD, SUITE 310, Houston, TX 77021
- EIN
- 33-0827593
- Ticker
- CNSY (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- CERENOME, INC. on the corporate pages
On this site
- Business registration: CYTORI THERAPEUTICS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: CERENOME, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: PLUS THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: CERENOME, INC. EXACT (CIK (EXACT))
- SEC filer: CYTORI THERAPEUTICS, INC. EXACT (CIK (EXACT))
- Person page: Marshall G Cox Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 60
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2016-04-06 | S-1 | S-1 (registration) | CYTORI THERAPEUTICS, INC. | 0001095981-16-000060 ↗ |
| 2016-05-11 | S-1/A | S-1/A (amendment) | CYTORI THERAPEUTICS, INC. | 0001095981-16-000077 ↗ |
| 2016-05-25 | S-1/A | S-1/A (amendment) | CYTORI THERAPEUTICS, INC. | 0001140361-16-066954 ↗ |
| 2016-05-26 | EFFECT | EFFECT (declared effective) | CYTORI THERAPEUTICS, INC. | 9999999995-16-004766 ↗ |
| 2016-05-27 | 424B4 | 424B4 (final prospectus) | CYTORI THERAPEUTICS, INC. | 0001140361-16-067434 ↗ |
| 2016-12-30 | S-1 | S-1 (registration) | CYTORI THERAPEUTICS, INC. | 0001564590-16-030543 ↗ |
| 2017-03-30 | EFFECT | EFFECT (declared effective) | CYTORI THERAPEUTICS, INC. | 9999999995-17-000698 ↗ |
| 2017-04-25 | EFFECT | EFFECT (declared effective) | CYTORI THERAPEUTICS, INC. | 9999999995-17-000945 ↗ |
| 2017-08-14 | S-1 | S-1 (registration) | CYTORI THERAPEUTICS, INC. | 0000950123-17-008026 ↗ |
| 2017-10-03 | S-1/A | S-1/A (amendment) | CYTORI THERAPEUTICS, INC. | 0000950123-17-008736 ↗ |
| 2017-10-27 | S-1/A | S-1/A (amendment) | CYTORI THERAPEUTICS, INC. | 0001564590-17-020306 ↗ |
| 2017-11-02 | EFFECT | EFFECT (declared effective) | CYTORI THERAPEUTICS, INC. | 9999999995-17-002846 ↗ |
| 2017-11-03 | 424B4 | 424B4 (final prospectus) | CYTORI THERAPEUTICS, INC. | 0001564590-17-021333 ↗ |
| 2018-04-10 | EFFECT | EFFECT (declared effective) | CYTORI THERAPEUTICS, INC. | 9999999995-18-000793 ↗ |
| 2018-04-27 | S-1 | S-1 (registration) | CYTORI THERAPEUTICS, INC. | 0000950123-18-003876 ↗ |
| 2018-06-06 | S-1/A | S-1/A (amendment) | CYTORI THERAPEUTICS, INC. | 0001564590-18-015100 ↗ |
| 2018-06-22 | EFFECT | EFFECT (declared effective) | CYTORI THERAPEUTICS, INC. | 9999999995-18-001600 ↗ |
| 2018-06-25 | 424B4 | 424B4 (final prospectus) | CYTORI THERAPEUTICS, INC. | 0001564590-18-016071 ↗ |
| 2018-07-12 | EFFECT | EFFECT (declared effective) | CYTORI THERAPEUTICS, INC. | 9999999995-18-001772 ↗ |
| 2018-07-13 | 424B4 | 424B4 (final prospectus) | CYTORI THERAPEUTICS, INC. | 0001564590-18-016821 ↗ |
| 2018-07-17 | S-1MEF | S-1MEF (added securities) | CYTORI THERAPEUTICS, INC. | 0000950123-18-006834 ↗ |
| 2018-09-21 | S-1 | S-1 (registration) | CYTORI THERAPEUTICS, INC. | 0001564590-18-023473 ↗ |
| 2018-10-05 | EFFECT | EFFECT (declared effective) | CYTORI THERAPEUTICS, INC. | 9999999995-18-002559 ↗ |
| 2019-02-01 | S-1 | S-1 (registration) | CYTORI THERAPEUTICS, INC. | 0001564590-19-001699 ↗ |
| 2019-09-10 | S-1/A | S-1/A (amendment) | PLUS THERAPEUTICS, INC. | 0001564590-19-034406 ↗ |
| 2019-09-16 | S-1/A | S-1/A (amendment) | PLUS THERAPEUTICS, INC. | 0001564590-19-034798 ↗ |
| 2019-09-23 | EFFECT | EFFECT (declared effective) | PLUS THERAPEUTICS, INC. | 9999999995-19-002148 ↗ |
| 2019-09-24 | 424B4 | 424B4 (final prospectus) | PLUS THERAPEUTICS, INC. | 0001564590-19-035317 ↗ |
| 2020-10-19 | EFFECT | EFFECT (declared effective) | PLUS THERAPEUTICS, INC. | 9999999995-20-002910 ↗ |
| 2020-10-29 | S-1 | S-1 (registration) | PLUS THERAPEUTICS, INC. | 0001193125-20-281074 ↗ |
| 2020-11-05 | EFFECT | EFFECT (declared effective) | PLUS THERAPEUTICS, INC. | 9999999995-20-003092 ↗ |
| 2021-02-26 | S-1 | S-1 (registration) | PLUS THERAPEUTICS, INC. | 0001193125-21-060556 ↗ |
| 2021-03-09 | EFFECT | EFFECT (declared effective) | PLUS THERAPEUTICS, INC. | 9999999995-21-000882 ↗ |
| 2021-09-03 | S-1 | S-1 (registration) | PLUS THERAPEUTICS, INC. | 0001193125-21-265606 ↗ |
| 2021-09-10 | EFFECT | EFFECT (declared effective) | PLUS THERAPEUTICS, INC. | 9999999995-21-003481 ↗ |
| 2022-08-09 | S-1 | S-1 (registration) | PLUS THERAPEUTICS, INC. | 0001193125-22-215328 ↗ |
| 2022-08-17 | EFFECT | EFFECT (declared effective) | PLUS THERAPEUTICS, INC. | 9999999995-22-002419 ↗ |
| 2023-08-09 | S-1 | S-1 (registration) | PLUS THERAPEUTICS, INC. | 0001193125-23-206816 ↗ |
| 2023-08-18 | EFFECT | EFFECT (declared effective) | PLUS THERAPEUTICS, INC. | 9999999995-23-002444 ↗ |
| 2023-11-14 | S-1 | S-1 (registration) | PLUS THERAPEUTICS, INC. | 0001193125-23-276323 ↗ |
| 2023-11-20 | EFFECT | EFFECT (declared effective) | PLUS THERAPEUTICS, INC. | 9999999995-23-003400 ↗ |
| 2023-11-22 | S-1 | S-1 (registration) | PLUS THERAPEUTICS, INC. | 0001193125-23-282240 ↗ |
| 2024-03-08 | S-1/A | S-1/A (amendment) | PLUS THERAPEUTICS, INC. | 0001193125-24-063694 ↗ |
| 2024-06-07 | S-1 | S-1 (registration) | PLUS THERAPEUTICS, INC. | 0001193125-24-157500 ↗ |
| 2024-06-24 | S-1/A | S-1/A (amendment) | PLUS THERAPEUTICS, INC. | 0001193125-24-166942 ↗ |
| 2024-06-24 | EFFECT | EFFECT (declared effective) | PLUS THERAPEUTICS, INC. | 9999999995-24-001930 ↗ |
| 2025-03-31 | RW | RW (withdrawal request) | PLUS THERAPEUTICS, INC. | 0001140361-25-011284 ↗ |
| 2025-06-18 | S-1 | S-1 (registration) | PLUS THERAPEUTICS, INC. | 0001193125-25-142215 ↗ |
| 2025-06-20 | S-1/A | S-1/A (amendment) | PLUS THERAPEUTICS, INC. | 0001193125-25-142935 ↗ |
| 2025-06-23 | RW | RW (withdrawal request) | PLUS THERAPEUTICS, INC. | 0001193125-25-144654 ↗ |
| 2025-06-23 | EFFECT | EFFECT (declared effective) | PLUS THERAPEUTICS, INC. | 9999999995-25-002000 ↗ |
| 2025-07-25 | RW | RW (withdrawal request) | PLUS THERAPEUTICS, INC. | 0001193125-25-165419 ↗ |
| 2025-08-12 | S-1 | S-1 (registration) | PLUS THERAPEUTICS, INC. | 0001193125-25-178940 ↗ |
| 2025-08-14 | EFFECT | EFFECT (declared effective) | PLUS THERAPEUTICS, INC. | 9999999995-25-002625 ↗ |
| 2026-01-09 | S-1 | S-1 (registration) | PLUS THERAPEUTICS, INC. | 0001193125-26-008922 ↗ |
| 2026-01-13 | S-1MEF | S-1MEF (added securities) | PLUS THERAPEUTICS, INC. | 0001193125-26-012091 ↗ |
| 2026-01-13 | EFFECT | EFFECT (declared effective) | PLUS THERAPEUTICS, INC. | 9999999995-26-000164 ↗ |
| 2026-01-14 | 424B4 | 424B4 (final prospectus) | PLUS THERAPEUTICS, INC. | 0001193125-26-012905 ↗ |
| 2026-03-06 | RW | RW (withdrawal request) | PLUS THERAPEUTICS, INC. | 0001193125-26-096495 ↗ |
| 2026-06-05 | EFFECT | EFFECT (declared effective) | PLUS THERAPEUTICS, INC. | 9999999995-26-001913 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Arm Douglas M | Officer | Sr. VP - Operations; Vice President Dev Reg Cell T; VP Development - RCT; VP Development, Reg. Techn. | 5 | 2006–2009 | |
| CALHOUN CHRISTOPHER J | Director,Officer; Officer | Chief Executive Officer | 33 | 2006–2014 | |
| GALETTO CHARLES | Officer | Sr. Vice President Finance & A | 1 | 2006 | |
| HEDRICK MARC H | Director,Officer; Officer | Chief Executive Officer; President; President and CEO; President & CEO | 62 | 2006–2026 | |
| Milstein Alexander M | Officer | Vice President Clinical Dev; Vice President Clinical Devel; Vice President Clinical Develo; VP - Clinical Development; VP Clinical Development | 6 | 2006–2009 | |
| Ransom John T | Officer | Vice President of Research; VP Research Regn. Cell Techn. | 2 | 2006–2007 | |
| REUTER BRUCE | Officer | Sen. VP Intern Sales, Marketin; Sr.Vice President Business Dev; SVP Sales, Market., Distr. | 6 | 2006–2009 | |
| Saad Mark E | Officer | Chief Financial Officer | 20 | 2006–2014 | |
| SCARBROUGH ELIZABETH | Officer | Vice President Marketing & Dev | 1 | 2006 | |
| SHIRAHAMA NORIO SEIJIRO | Officer | President - Asia Pacific; President, Asia Pacific; Senior Vice President Asia Pac; Senior VP Asia Pacific; SVP Asia Pacific; Vice President Asia Pacific | 21 | 2006–2015 | |
| COX MARSHALL G | Director | 3 | 2006–2007 | person page Fuzzy | |
| HAWRAN PAUL W | Director | 23 | 2006–2017 | ||
| HENRIKSEN RONALD D | Director | 13 | 2006–2012 | ||
| HOLMES E CARMACK | Director | 15 | 2006–2014 | ||
| RICKEY DAVID | Director | 56 | 2006–2017 | ||
| OLYMPUS CORP | TenPercentOwner | 2 | 2006–2008 | ||
| Hawkins Richard J | Director | 31 | 2007–2026 | ||
| Dean Lloyd H | Director | 11 | 2010–2014 | ||
| Townsend John | Officer | Controller | 5 | 2011–2015 | |
| Thompson Tommy G | Director | 12 | 2011–2016 | ||
| LYONS GARY A | Director | 9 | 2013–2018 | ||
| Lim Kian Thiam | TenPercentOwner | 2 | 2014–2015 | ||
| Jona Ruud J.P. | Director | 2 | 2014 | ||
| Naughton Gail K | Director | 7 | 2014–2017 | ||
| Girao Tiago | Officer | VP & Chief Financial Officer | 13 | 2014–2018 | |
| HAYDEN JEREMY B. | Officer | General Counsel & VP of BD | 8 | 2015–2017 | |
| KESTEN STEVEN | Officer | Exec VP and Chief MO | 5 | 2015–2016 | |
| HARRIS JOHN DAVID | Officer | VP and GM Cell Therapy; VP and GM of Cell Therapy | 9 | 2015–2017 | |
| Marino Mark | Officer | Chief Medical Officer | 3 | 2016–2017 | |
| MARTELL RON | Director | 2 | 2017 | ||
| LAPOINTE ANTHONY GREGG | Director | 2 | 2017 | ||
| Swissquote Bank SA | TenPercentOwner | 2 | 2018 | ||
| PostFinance AG | TenPercentOwner | 4 | 2018 | ||
| van Es-Johansson An | Director | 11 | 2020–2026 | ||
| Sims Andrew John Hugh MacIntyre | Officer | Chief Financial Officer | 24 | 2020–2026 | |
| Petersen Greg | Director | 14 | 2020–2025 | ||
| Clowes Howard | Director | 17 | 2020–2026 | ||
| Lenk Robert P | Director | 16 | 2020–2025 | ||
| LaFrance Norman D. | Officer | Chief Medical Officer; CHIEF MEDICAL OFFICER | 5 | 2021–2024 | |
| Guse Kyle | Director | 4 | 2025–2026 | ||
| ANDREWS RONALD ASBURY | Director | 3 | 2026 | ||
| Daniels Eric Joseph | Officer | Chief Development Officer | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-09-18 | CERENOME, INC. | Other Health Care | $20,000,000 | $3,000,000 | 1 | 1 |
| 2020-05-22 | PLUS THERAPEUTICS, INC. | Pharmaceuticals | $300,000 | $300,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.